Pulse Biosciences/$PLSE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pulse Biosciences
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
- Ticker
- $PLSE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 116
- Headquarters
- Miami, United States
- Website
- www.pulsebiosciences.com
PLSE Metrics
BasicAdvanced
$3.8B
-
-$1.21
-
-
Price and volume
Market cap
$3.8B
52-week high
$58.90
52-week low
$12.56
Average daily volume
407K
Financial strength
Current ratio
14.349
Quick ratio
14.146
Long term debt to equity
0.025
Total debt to equity
0.035
Profitability
EBITDA (TTM)
-86.538
Gross margin (TTM)
26.77%
Net profit margin (TTM)
-5,603.88%
Operating margin (TTM)
-5,861.24%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-35.27%
Return on equity (TTM)
-60.61%
Valuation
Price to revenue (TTM)
2,469.759
Price to book
21.28
Price to tangible book (TTM)
21.62
Price to free cash flow (TTM)
-57.923
Free cash flow yield (TTM)
-1.73%
Free cash flow per share (TTM)
-0.92
Growth
Revenue change (TTM)
1,637.21%
Earnings per share change (TTM)
6.73%
3-year revenue growth (CAGR)
449.59%
3-year earnings per share growth (CAGR)
11.11%
10-year earnings per share growth (CAGR)
4.12%
What the Analysts think about PLSE
Analyst ratings (Buy, Hold, Sell) for Pulse Biosciences stock.
Analyst projections of the future price of Pulse Biosciences stock.
Bulls say / Bears say
The European feasibility study reported 96% freedom from atrial fibrillation at one year in its five-second treatment group and a 1.7% serious adverse-event rate across 177 patients. These early results suggest the catheter could offer an effective option, although they still need confirmation in larger trials. (The Cardiology Advisor)
Pulse reached its target of 164 evaluable patients in the US pivotal NANOPULSE-AF study across 15 sites. Completing enrolment is an execution milestone that moves the programme towards its safety and effectiveness readouts. (Pulse Biosciences)
The company says some physicians achieved ablation times of seven to eight minutes or less in their first cases, while several sites performed five or more cases in a day. If this workflow advantage holds up, it could help hospitals handle more procedures. (Pulse Biosciences)
The US pivotal study is non-randomised, and its primary safety and effectiveness results still depend on six- and 12-month follow-up. The earlier European study was also observational, so the reported results do not yet establish how the catheter compares with existing treatments. (Pulse Biosciences, The Cardiology Advisor)
Commercial sales remain very small: second-quarter revenue was $434,000, against a $24.7 million net loss and $18.7 million of operating cash use. The company remains dependent on future adoption to narrow that gap. (Pulse Biosciences)
Pulse raised $46.8 million through share sales in the second quarter and set up a further $75 million at-the-market facility. More equity sales could fund development but dilute existing shareholders. (Pulse Biosciences, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
PLSE Financial Performance
Revenues and expenses
PLSE Earnings Performance
Company profitability
Upcoming events
No upcoming events
PLSE News
AllArticlesVideos
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call
MarketBeat22 hours ago
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Business Wire3 weeks ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire4 weeks ago
Funds containing PLSE
Fund name | Fund size | $PLSE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.03% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.03% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.